Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data

    DarioHealth Corp. Logo

    News provided by

    DarioHealth Corp.

    16 Nov, 2026, 14:30 IST

    Share this article

    Share this article


    New methodology addresses critical market need for a transparent, replicable model to estimate healthcare cost savings and ROI when medical claims data are unavailable or delayed

    Further demonstrates Dario's economic value in support of new contract wins, contract renewals and expansion of existing customer relationships

    NEW YORK, Nov. 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the presentation of new research at ISPOR Europe 2026, a leading international conference focused on health economics and outcomes research, held November 8–11 in Vienna, Austria. The research highlights Dario's methodology for estimating healthcare cost savings and return on investment ("ROI") based on biometric improvements achieved by members participating in digital chronic disease management programs.

    The presentation, titled "Estimating Individual-Level Medical Cost Savings from Digital Chronic Disease Management: A Biometric-to-PMPM Proxy Methodology," was delivered by Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at DarioHealth. The research describes a retrospective model that translates observed changes in blood pressure, blood glucose and weight into projected reductions in healthcare expenditures using published medical cost data.

    Dario's model addresses the need among health plans, employers and enterprise healthcare purchasers to link measurable clinical outcomes to estimated cost savings. Leveraging the model, Dario is able to provide customers with evidence of program value in support of purchasing decisions, contract renewals and expansion into additional conditions and populations – without waiting for medical claims data, which often take months to become available or may not be accessible.

    "This is a powerful study that provides an evidence-based and replicable method to demonstrate the in-year cost savings that Dario delivers specific to cardiometabolic disease. Moreover, it quantifies how savings are amplified when multiple conditions are enrolled," said Erez Raphael, Chief Executive Officer of DarioHealth. "This research gives Dario clients a validated process to confirm that their investment in Dario for cardiometabolic health is delivering the cost savings they contracted for – without the added administrative costs, time or reliance on claims analysis when claims data are delayed or not available."

    "One of the biggest challenges in demonstrating the economic value of digital health is the limited availability of timely medical claims data," said Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at DarioHealth. "Our methodology bridges that gap directly by translating observed changes in clinical measures into transparent, evidence-based estimates of potential healthcare savings. This gives healthcare purchasers a practical way to evaluate program performance and understand its potential financial impact."

    About DarioHealth Corp.

    DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

    Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution. 

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits, applicability and reliability of its biometric-driven methodology for estimating healthcare cost savings and return on investment; the ability of the methodology to estimate potential healthcare cost savings without medical claims data; the potential economic value of the Company's digital chronic disease management programs, including the potential for increased savings associated with managing multiple conditions; and the potential use of the methodology to support customer purchasing decisions, new customer relationships, contract renewals and the expansion of existing customer relationships. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contacts

    Michael Lipari
    SVP Corporate Development
    [email protected] 
    +1-201-785-6310

    Rob Halpern
    SVP Marketing
    [email protected] 

    SOURCE DarioHealth Corp.

    Modal title

    Also from this source

    /C O R R E C T I O N - DarioHealth Corp./

    /C O R R E C T I O N - DarioHealth Corp./

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the...

    Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

    Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

    DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.